Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $494,726.

  • Capricor Therapeutics' Depreciation & Amortization (CF) rose 36.98% to $494,726 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 29.85%. This contributed to the annual value of $1.4 million for FY2024, which is 33.34% up from last year.
  • According to the latest figures from Q3 2025, Capricor Therapeutics' Depreciation & Amortization (CF) is $494,726, which was up 1.74% from $486,278 recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Depreciation & Amortization (CF) ranged from a high of $494,726 in Q3 2025 and a low of $50,137 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $356,935 (2024), whereas its average is $352,777.
  • Data for Capricor Therapeutics' Depreciation & Amortization (CF) shows a peak YoY soared of 148.78% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Capricor Therapeutics' Depreciation & Amortization (CF) stood at $78,645 in 2021, then skyrocketed by 143.63% to $191,602 in 2022, then skyrocketed by 60.55% to $307,608 in 2023, then climbed by 22.14% to $375,705 in 2024, then surged by 36.98% to $494,726 in 2025.
  • Its last three reported values are $494,726 in Q3 2025, $486,278 for Q2 2025, and $405,450 during Q1 2025.